1 – 10 of 14
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Effect of GB1107, a novel galectin-3 inhibitor on pro-fibrotic signalling in the liver
(
- Contribution to journal › Article
-
Mark
Development and Characterization of a High-Affinity Selective Galectin-3 Mouse Tool Compound in Mouse Models of Cancer
(
- Contribution to journal › Article
-
Mark
Discovery of the Selective and Orally Available Galectin-1 Inhibitor GB1908 as a Potential Treatment for Lung Cancer
(
- Contribution to journal › Article
- 2023
-
Mark
Resistance to anti-PD-1/anti-PD-L1 : galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
(
- Contribution to journal › Article
-
Mark
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor : a single- and multiple-dose first-in-human study in healthy participants
(
- Contribution to journal › Article
- 2022
-
Mark
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease
(
- Contribution to journal › Article
-
Mark
Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation
(
- Contribution to journal › Article
- 2021
-
Mark
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis
(
- Contribution to journal › Article
- 2019
-
Mark
An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade
(
- Contribution to journal › Article
- 2016
-
Mark
A Selective Galactose–Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model
(
- Contribution to journal › Article